Research & Development

Projects in development


The only way to innovation is to take charge of everyone's needs and solve common problems.

The R&D of bio-digital therapies that can provide the highest quality and quantity of health to the person with disease is one of Polifarma's primary goals as a modern pharmaceutical company.

Alongside the biological intervention, the modification of cellular functions through interaction with a receptor, today digital technology allows to help patients to modify their behaviors, which in the majority of chronic diseases are the basis or the fundamental component of the disease.

Check out our Pipeline on current projects.

* in co-development with daVi Digital Medicine S.r.l.

QK-D - Hypertension

Therapeutic Area
The diagnosis of hypertension and its treatment can significantly reduce the risk of future cardiovascular events. However, despite the availability of numerous pharmacological options, the rates of achievement of blood pressure goals and control of hypertension remain suboptimal.
Improving the management of hypertension may therefore require combined approaches with different health technologies.

Project Purpose
To develop a Digital Medical Device "QK-D" as a Digital Therapeutic for the treatment of hypertension, which can be used either individually or in combination with an antihypertensive drug from Polifarma.
The aim is to improve the patient's management of hypertension and to increase the therapeutic efficacy of antihypertensive treatment in "real life" conditions.

DarSana – Ophthalmology

Therapeutic Area
In Italy eye diseases, that lead to the progressive loss of patient autonomy, result in increased economic and social costs. Pathologies such as diabetic retinopathy, glaucoma, uncorrected refractive errors and cataracts are the main causes of visual impairment and blindness.
Worldwide, at least 2.2 billion people have near or far vision impairment; in almost half of the cases, vision impairment could have been prevented.
Considering this context, in a recent resolution, WHO recommends the implementation of technological innovations in addition to more traditional interventions. (WHA 73,4)

Project Purpose
Development of a Digital Prescription Medical Device (DarSanadm) for telecontrol of visual acuity and metamorphopsia independently by the patient with age-related macular degeneration (AMD).

ISO-D – Gastroenterology

Therapeutic Area
Colorectal cancer is a major cause of morbidity and mortality worldwide, with an increase in cases due to the pandemic and delays in screening. Colonoscopy is an important screening tool that has reduced the incidence of CRC, but adherence is limited and the quality of bowel preparation is often inadequate.
Inadequate bowel preparation can have several negative implications for proper endoscopic evaluation. Given the complexity of exam preparation for colonoscopy, it is necessary to educate patients to perform bowel preparation satisfactorily.

Project Purpose
To develop a Digital Medical Device - “ISO-D dm“, as Digital Support to a Polifarma's macrogol-based drug licensed for "bowel cleansing" for preparing patients for colonoscopy.
The project involves the device being able to inform/support/guide the patient, in the preparation phase for colonoscopy: from diet, to the correct preparation and intake of the liquid preparation of the drug.

IC-D – Chronic Insomnia

Therapeutic Area
Chronic insomnia refers to the difficulty in reconciling or maintaining sleep that occurs for at least three nights a week for a period of three months or more. Causes of chronic insomnia may include medical or psychological disorders such as depression, anxiety, chronic pain or physical health problems. Treatment of chronic insomnia usually involves a combination of lifestyle changes, behavioral therapy and, in some cases, prescription medication. Bio-Digital therapies can support the treatment of insomnia.

Project Purpose
Development of a Medical Device “IC-Ddm” in the form of a digital app with the purpose of Digital Therapeutics for the treatment of chronic insomnia in association or combination with melatonin medication or dietary supplement.

Work with us

At Polifarma, every day a group of about 140 professionals, including internal employees and the external network, works closely sharing knowledge, skills and expertise.

Discover more


Polifarma SpA - Share Capital €1,000,000.00 - fully paid up Comp. Register Rome - Tax Code 00403210586 - Economic Index (REA) Rome No. 11913 - VAT No. 00882341001